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 A rapid one-step reverse transcription-loop-mediated isothermal amplification (RT-2 
LAMP) assay targeting the pol-integrase gene was developed to detect human 3 
immunodeficiency virus type 1 (HIV-1) group M. This HIV-1 RT-LAMP assay is 4 
simple and rapid, and amplification can be completed within 35 min under isothermal 5 
conditions at 60°C. The 100% detection limit of HIV-1 RT-LAMP was determined 6 
using a standard strain (WHO HIV-1 [97/656]) in octuplicate and found to be 120 7 
copies/ml. The RT-LAMP assay was evaluated for use in clinical diagnosis using   8 
plasma samples collected from 57 HIV-1-infected and 40 uninfected individuals in 9 
Cameroon, where highly divergent HIV-1 strains are prevalent. Of the 57 samples from 10 
infected individuals, 56 harbored group-M HIV-1 strains, such as subtypes A, B, G, F2, 11 
and circulating recombinant forms (CRF)_01, _02, _09, _11, _13; all were RT-LAMP 12 
positive. One sample harboring group-O HIV-1 and the 40 HIV-1-uninfected samples 13 
were RT-LAMP negative. These findings indicate that HIV-1 RT-LAMP can detect 14 
HIV-1 group-M RNA from plasma samples rapidly and with high sensitivity and 15 
specificity. These data also suggest that this RT-LAMP assay can be useful for 16 
confirming HIV diagnosis, particularly in resource-limited settings. 17 
 18 
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1. Introduction 1 
The number of people living with human immunodeficiency virus (HIV) infection 2 
was estimated at 33 million as of December 2007, and over 2.7 million people acquired 3 
new HIV infections in 2007 (UNAIDS, 2008). HIV testing and counseling have been 4 
recognized as entry points for prevention, care, treatment, and support (World Health 5 
Organization, 2004). Recently, rapid serological HIV tests have been introduced to 6 
facilitate radical scaling up of HIV testing and counseling services in many settings, 7 
such as in diagnosing and treating sexually transmitted infections, in services providing 8 
and linked to the prevention of mother-to-child transmission, and in general medical 9 
settings (World Health Organization, 2004). It has been shown that sequential 10 
combinations of two or three antibody (Ab) tests (ELISA and/or rapid tests) are reliable 11 
for confirming HIV-positivity (World Health Organization, 2004; Aghokeng et al., 12 
2004; Carvalho et al., 1996; Meda et al, 1999). However, considering that the fourth 13 
generation HIV ELISA test, which can detect both HIV P24 antigen and HIV Ab in the 14 
same sample simultaneously, has been introduced to detect early-stage HIV infection 15 
(Meda et al., 1999) and that a combined antigen-Ab rapid test for diagnosing HIV will 16 
be introduced soon (Keren et al, 2008), a method for rapidly detecting HIV-1 RNA 17 
and/or proviral DNA to confirm HIV diagnosis in these settings would be a valuable 18 
diagnostic aid.  19 
HIV-1 is classified into three groups: M, N, and O. Group M, which accounts for 20 
the HIV pandemic, is further classified into nine major clades (A-D, F-H, J, and K) and 21 
 4 
42 circulating recombinant forms (CRFs; Heeney et al., 2006; Powell et al., 2007; HIV 1 
sequence Compendium 2008). The diverse nature of HIV causes difficulties in 2 
nucleotide-based diagnoses of HIV infection. In addition, low HIV DNA burden and 3 
low concentrations of HIV RNA in plasma often result in failure to detect HIV RNA or 4 
DNA in clinical specimens (Zazzi et al., 1995). These two factors, high diversity and 5 
low plasma RNA/proviral DNA concentration, limit the ability to diagnose HIV 6 
infection reliably and efficiently. 7 
The reverse transcription-loop-mediated isothermal amplification (RT-LAMP) assay 8 
developed by Notomi is a simple method for nucleotide-based diagnostics that exhibits 9 
high sensitivity and specificity (Notomi, et al., 2000). This method relies on auto-10 
cycling strand displacement DNA synthesis by a DNA polymerase with high strand 11 
displacement activity and a set of two each of specially designed inner and outer primers. 12 
The entire RT-LAMP procedure can be completed in a single step at a constant 13 
temperature without a programmed thermal cycler. LAMP provides highly efficient 14 
DNA amplification, up to 109-1010 times in 15-60 min, and the concentration of the 15 
LAMP product is much higher than that generated by conventional polymerase chain 16 
reaction (PCR). Conventional PCR is relatively time consuming (3-4 h) and much more 17 
complicated than RT-LAMP, requiring several amplification steps and the use of a 18 
high-precision thermal cycler. The RT-LAMP assay has been validated and applied to 19 
the rapid detection of a number of RNA viruses, such as rubella virus (Mori et al., 2006), 20 
Japanese encephalitis virus (Toriniwa and Komiya, 2006), influenza virus (Ito et al., 21 
 5 
2006), mumps virus (Okafuji et al., 2005), West Nile virus (Parida et al., 2004), severe 1 
acute respiratory syndrome corona virus (Hong et al., 2004; Poon et al., 2005), measles 2 
virus (Fujino et al., 2005), dengue virus (Parida et al., 2005), respiratory syncytial virus 3 
(Ushio et al., 2005), and HIV-1 (Curtis et al., 2008) .  4 
In the present study, another RT-LAMP assay was developed for the rapid detection 5 
of HIV-1 RNA. Its intended application is on-site confirmation of HIV diagnosis.  6 
 7 
2. Materials and methods 8 
2.1. Standard serum 9 
WHO standard 97/656 (105 international units (IU) per vial, National Institute for 10 
Biological Standards and Control, Herts, UK) was used to determine the detection limit 11 
of the RT-LAMP assay (Davis et al., 2003; Holmes et al., 2001). The assay was carried 12 
out in octuplicate. The lowest concentration of genome copies with all octuplicate 13 
samples confirmed as positive was considered the detection limit. 14 
 15 
2.2. Human plasma samples 16 
Plasma samples were collected from 57 HIV-1-infected individuals in eastern 17 
Cameroon in 2001 (Ndembi et al., 2004) and 40 HIV-1-uninfected antenatal clinic 18 
attendees in western Cameroon in 2003. These samples were used to evaluate the 19 
sensitivity and specificity of HIV-1 RT-LAMP. In a previous study (Ndembi et al., 20 
2004), phylogenetic analysis of genomic DNA samples from the 57 infected individuals 21 
 6 
revealed the presence of highly divergent strains of HIV-1 circulating in eastern 1 
Cameroon (Table 1). The 40 samples from uninfected individuals collected in 2003 2 
were confirmed HIV-negative by HIV-Ab testing (AxSYM HIV1/2 and/or Determine 3 
HIV-1/2; Abbott Japan, Tokyo, Japan) and conventional PCR, as described previously 4 
(Ndembi et al., 2004). 5 
 6 
2.3. RNA preparation 7 
HIV RNA was extracted from plasma as follows: 200 µl of plasma was incubated 8 
with 400 µl of lysis buffer consisting of 10 mM Tris-HCl (pH 8.0), 68% (w/v) 9 
guanidine isothiocyanate, 3% (w/v) dithiothreitol, and 4 µl of co-precipitant (10 mg/ml 10 
amylopectin azure) at 25°C for 10 min. HIV RNA was precipitated by adding 600 µl of 11 
isopropanol and centrifuging at 20,000×g for 15 min. The RNA pellet was washed with 12 
70% ethanol and resuspended in 10 µl of RNAse-free and DNAse-free water.  13 
 14 
2.4. Primer design 15 
A set of primers that recognizes eight distinct target sites in the HIV-1 pol-integrase 16 
gene, a well-conserved region of HIV-1 genome, was designed based on the HIV-1 17 
genome sequence (GenBank accession number K02013) using a primer-designing 18 
software program for LAMP (Primer Explorer ver. 2.0; Net laboratory, Japan, 19 
http://venus.netlaboratory.com; Table 2). The set consisted of the six following primers: 20 
a forward inner primer (FIP), backward inner primer (BIP), two outer primers (F3 and 21 
 7 
B3), and two loop primers (Loop F and Loop B). Two additional inner primers 1 
comprise the combination of two functionally different primer parts: FIP consists of F1c 2 
(complementary to F1) and F2 and BIP consists of B1c (complementary to B1) and B2. 3 
The sequences of the two loop primers are complementary to the primers located 4 
between regions corresponding to F1 and F2 primer sequences. 5 
 6 
2.5. RT-LAMP assay 7 
The RT-LAMP reaction was carried out in 25 µl using a Loopamp DNA 8 
amplification kit (EIKEN Chemical Co., Ltd., Tochigi, Japan) containing FIP (40 pmol), 9 
BIP (40 pmol), F3 (5 pmol), B3 (5 pmol), Loop F (40 pmol), Loop B (40 pmol), Bst 10 
DNA polymerase (16 U), AMV reverse transcriptase (2 U), and 5 µl of target RNA. The 11 
reaction mixture was incubated at 60°C for 60 min in a Loopamp real-time turbidimeter 12 
(LA-200; Teramecs, Kyoto, Japan; Fig. 1A). A turbidity value of more than 0.1 was 13 
considered positive. The amplified products of RT-LAMP were resolved by 2% agarose 14 
gel electrophoresis (Agarose S; Wako Pure Chemical Industries, Ltd, Osaka, Japan); the 15 
gel was stained with ethidium bromide and visualized using an ultraviolet (UV) 16 
transilluminator (Fig. 1B). The turbidity of the amplified products was also ascertained 17 
by naked eye. The amplified products were inspected further under UV irradiation with 18 
or without adding ethidium bromide, an intercalating dye, when RT-LAMP assay was 19 
carried out in the presence of Fluorescent Detection Reagent (EIKEN CHEMICAL Co., 20 
LTD., Tokyo, Japan; Fig. 1C). 21 
 8 
 1 
3. Results 2 
3.1. Development of the HIV-1 RT-LAMP assay 3 
Using the primer sets targeting the HIV-1 pol-integrase gene (Table 2), a one-step 4 
RT-LAMP assay for the rapid detection of HIV-1 RNA was standardized. The success 5 
of amplification was assessed using a real-time turbidimeter (LA-200; Fig. 1A). 6 
Threshold time (Tt), the time required for the turbidity value to exceed 0.1, is shown in 7 
Table 1. Amplification was also detected by the presence of a ladder-like pattern on a 8 
2% agarose gel. The ladder-like pattern results from a mixture of stem-loop DNAs of 9 
various stem lengths and cauliflower-like structures with multiple loops (formed by 10 
annealing between alternately inverted repeats of the target sequence in the same strand; 11 
Fig. 1B). Furthermore, amplification was detected by naked-eye inspection of turbidity; 12 
visual detection was enhanced further by the addition of Fluorescent Detection Reagent 13 
and/or the intercalating dye under UV irradiation (Fig. 1C).  14 
 15 
3.2. Sensitivity and specificity of the HIV-1 RT-LAMP assay 16 
The sensitivity of the RT-LAMP assay for detecting HIV-1 RNA was determined 17 
using RNA from WHO standard HIV-1 97/656 (105 IU/vial) diluted to 6000, 600, 240, 18 
120, 90, and 60 copies/ml. One IU was reported to be equivalent to 0.62 genome copies 19 
(Davis et al., 2003). The assay was carried out in octuplicate using viral RNA extracted 20 
 9 
from the equivalent of 100 µl of diluted serum. The reproducible 100% detection limit 1 
of the RT-LAMP assay was 120 copies/ml. 2 
Of the 57 HIV-1-positive samples, 54 were positive for RT-LAMP in 19.2 to 33.2 3 
min as assessed by turbidity using the LA-200 detection system (Table 1 and Fig. 1A). 4 
HIV-1 RT-LAMP products of the two samples that were not detected by the real-time 5 
turbidimeter (01CM2219 and 01CM2232) could be detected by agarose gel 6 
electrophoresis (Fig. 1B) and by the naked eye after adding the intercalating dye under 7 
UV irradiation in the presence of Fluorescent Detection Reagent (data not shown). The 8 
remaining sample (02CM319) containing HIV-1 group-O RNA was RT-LAMP 9 
negative (Table 1 and Fig. 1B). Thus, all 56 samples that harbored HIV-1 group-M 10 
were positive by HIV-1 RT-LAMP assay.  11 
Plasma specimens obtained from 40 pregnant women without HIV infection were 12 
also subjected to RT-LAMP and all were confirmed negative. 13 
 14 
4. Discussion 15 
An RT-LAMP assay was developed to detect HIV-1 RNA. This method was simple, 16 
rapid, and highly sensitive and specific for group-M HIV-1. Therefore, the HIV-1 RT-17 
LAMP assay can be used as a rapid confirmatory test for HIV-1 group-M infection. 18 
The HIV genome is usually detected by RT-PCR and PCR performed on plasma 19 
RNA and proviral DNA, respectively. These methods require at least 2-3 hours despite 20 
the implementation of real-time PCR. In this study, the HIV-1 RT-LAMP assay was 21 
 10 
completed within 35 min, considerably faster than by RT-PCR or PCR. In addition, 1 
unlike RT-PCR and PCR, a simple apparatus such as a water bath can be used to 2 
maintain the constant incubation temperature at 60°C. 3 
The RT-LAMP reaction yields a white precipitate of magnesium pyrophosphate in 4 
the reaction mixture, indicating a positive result. This white precipitate is easily 5 
detected by the naked eye (Fig. 1C); thus, the results of the assay can be assessed 6 
without a turbidimeter. Although the amount of HIV-1 RT-LAMP products was 7 
monitored by a real-time turbidimeter (LA-200) in the current study, the results of 8 
visual inspection were consistent with those determined by turbidimeter (data not 9 
shown). According to the manufacturer’s instructions for the Loopamp DNA 10 
amplification kit, visual detection can be enhanced by the addition of Fluorescent 11 
Detection Reagent to the reaction mixture. Interestingly, HIV-1 RT-LAMP products of 12 
the two samples that were undetectable by LA-200 (01CM2219 and 01CM2232) could 13 
be visualized by adding the intercalating dye under UV irradiation, when the assay was 14 
carried out in the presence of Fluorescent Detection Reagent. Thus, the HIV-1 RT-15 
LAMP assay has the advantage of enabling the amplification of HIV-1 RNA and/or 16 
DNA in resource-limited settings in which sophisticated machines such as the thermal 17 
cycler and real-time turbidimeter are unavailable. In the two samples that were not 18 
detected by LA200, the production of magnesium pyrophosphate was prevented by 19 
unknown inhibitor(s). The cause and frequency of this phenomenon are under 20 
investigation. 21 
 11 
RT-LAMP assay exhibits high specificity due to its use of multiple primers, 1 
including two loop primers, that recognize eight distinct regions of the target sequences. 2 
Previous studies in which RT-LAMP was used to detect various viral RNAs have 3 
documented the high specificity of RT-LAMP (Mori et al., 2006; Toriniwa et al., 2006; 4 
Ito et al., 2006; Okafuji et al., 2005; Parida et al., 2004; Hong et al., 2004; Poon et al., 5 
2005; Fujino et al., 2005; Parida et al, 2005; Ushio et al., 2005). Similarly, HIV-1 RT-6 
LAMP analysis of 40 sero-negative and PCR-negative samples showed 100% 7 
specificity, making the RT-LAMP assay ideal for confirming diagnosis. 8 
The 100% detection limit of the HIV-1 RT-LAMP assay was found to be 120 9 
copies/ml (12 copies/100 µl/assay). This sensitivity is inferior to the quantification limit 10 
(50 copies/ml) of the UltraSensitive Assay of the COBAS AMPLICOR HIV-1 11 
MONITOR test, v 1.5 (Roche), but superior to the detection limit of the Standard Assay 12 
in the kit (400 copies/ml), and typical RT-PCR assays. Furthermore, the sensitivity of 13 
the current HIV-1 RT-LAMP could be improved to reach or exceed that of the 14 
UltraSensitive Assay by using a larger initial plasma sample (more than 240 µl) for 15 
extracting viral RNA. 16 
The HIV-1 RT-LAMP assay was evaluated using 57 HIV-1 strains belonging to 17 
nine different group-M subtypes/CRFs and one group O based on gag and pol 18 
sequences, respectively (Table 1): subtypes A (n = 3), B (n = 6), F2 (n = 1), G (n = 1), 19 
CRF_01AE (n = 8), CRF_02.AG (n = 17), CRF_09.cpx (n = 1), CRF_11.cpx (n = 16), 20 
CRF_13.cpx (n = 3), and group O (n = 1; Ndembi et al., 2004). This assay system 21 
 12 
identified all of the 56 group-M HIV-1 strains despite their diversity, but did not detect 1 
the group-O strain, indicating that the primers used in the current HIV-1 RT-LAMP 2 
assay were group-M specific. Thus, in order to detect not only all of the HIV-1 groups 3 
but HIV type-2 strains as well, the design of universal primer set will be necessary.  4 
Although the viral RNA extraction method used in this study is relatively easy and 5 
cheap as compared to conventional methods, it still requires knowledge and training not 6 
usually available in resource-limited settings. Therefore, it will be necessary to revise 7 
and simplify the extraction method in order to use this assay as a confirmatory test for 8 
HIV diagnosis in the field. Future evaluation of the direct use of plasma or serum after 9 
heating as a test material is warranted (Curtis et al., 2008).   10 
In conclusion, a one-step RT-LAMP assay for detecting group-M HIV-1 has been 11 
developed. The RT-LAMP assay is simple, rapid, and highly sensitive and specific for 12 
group-M HIV-1; therefore, this assay can be used to confirm group-M HIV-1 diagnosis. 13 
Once the RNA extraction method is simplified, the group-M HIV-1 RT-LAMP assay 14 
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Figure captions 1 
 2 
Fig.1. Real-time detection of HIV-1 RT-LAMP products of 57 HIV-1-positive samples 3 
from Cameroon by turbidmeter (LA-200). (A) Agarose gel electrophoresis of HIV-1 4 
RT-LAMP products that were undetectable by LA-200. A turbidity value of more than 5 
0.1 was considered positive. Turbidity of three samples (01CM2219, 01CM2232, and 6 
02CM319) was less than 0.1. (B-C) Representative pictures of HIV-1 RT-LAMP 7 
products with (B) and without (C) Fluorescent Detection Reagent. (B) Lane 1: 8 
01CM2219; lane 2: 01CM2232; lane 3: 02CM319; and lane 4: 01CM2213 (positive 9 
control). (C) HIV-1 RT-LAMP positive (+) and negative (-). FDR: Fluorescent 10 
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TABLE 1. HIV-1 genotype data for 57 infected individuals from eastern Cameroon and the 
results of HIV-1 RT-LAMP.  
Genetic subtypea LAMP 
Sample ID 
gag pol envC2V3 gp41 Tte EP 
01CM2213 CRF_01.AE nac CRF_01.AEA na 19.2f Pg 
01CF2214 G U U na 25.8 P 
01CM2215 CRF_02.AG na CRF_02.AG na 28.7 P 
01CM2216 A na A na 21.2 P 
01CM2217 CRF_11.cpx na CRF_11.cpx na 26.5 P 
01CM2218 CRF_11.cpx CRF_11.cpx nd U 31.0 P 
01CM2219 CRF_11.cpx na CRF_02.AG na No Tt P 
01CM2220 CRF_02.AG na A na 29.2 P 
01CM2222 CRF_02.AG na CRF_02.AG na 29.2 P 
01CM2223 CRF_01.AE na CRF_02.AG na 26.2 P 
01CM2224 CRF_02.AG na CRF_02.AG na 28.8 P 
01CM2225 B na A na 24.3 P 
01CM2226 CRF_02.AG na CRF_02.AG na 26.4 P 
01CM2227 CRF_02.AG na CRF_02.AG na 27.2 P 
01CM2228 CRF_02.AG na CRF_02.AG na 30.9 P 
01CM2229 CRF_11.cpx na CRF_11.cpx na 27.0 P 
01CM2230 A na A na 22.7 P 
01CM2231 CRF_02.AG na A na 23.4 P 
01CM2232 B U A U No Tt P 
01CM2234 CRF_11.cpx na CRF_02.AG na 26.0 P 
01CM2235 B U nd U 21.9 P 
01CM2236 CRF_02.AG na CRF_02.AG na 25.2 P 
01CM2237 F2 na F2 na 25.1 P 
01CM2238 CRF_13.cpx na CRF_01.AE na 22.2 P 
01CM2239 CRF_13.cpx na CRF_11.cpx na 26.2 P 
01CM2240 CRF_02.AG na CRF_13.cpx na 29.6 P 
01CM2241 CRF_01.AE CRF_11cpx nd U 27.5 P 
01CM2242 CRF_02.AG na CRF_02.AG na 24.8 P 
01CM2243 CRF_11.cpx CRF_11cpx nd CRF_11.cpx 24.7 P 
01CM2244 CRF_01.AE na CRF_11.cpx na 23.1 P 
01CM2246 B na CRF_01.AE na 23.6 P 
01CF2247 CRF_11.cpx na CRF_01.AE na 24.1 P 
01CM2248 CRF_01.AE na A na 21.9 P 
01CM2249 A na A na 23.6 P 
01CM2250 CRF_02.AG CRF_02.AG nd U 30.5 P 
01CM2252 CRF_02.AG U nd U 28.6 P 
01CM2253 CRF_01.AE U nd A 21.7 P 
01CM2256 CRF_01.AE na A na 21.6 P 
01CM2257 CRF_01.AE na A na 21.9 P 
01CM2260 CRF_13.cpx U A CRF_13.cpx 23.7 P 
01CM2262 B na CRF_02.AG na 27.8 P 
01CF2268 CRF_02.AG CRF_02.AG nd CRF_02.AG 32.5 P 
01CM2269 CRF_11.cpx CRF_11.cpx nd CRF_11.cpx 26.7 P 
01CM2270 CRF_02.AG CRF_02.AG nd U 31.9 P 
01CM2271 CRF_11.cpx CRF_02.AG nd CRF_11.cpx 23.9 P 
01CM2272 CRF_11.cpx na CRF_11.cpx na 21.2 P 
01CM2273 CRF_11.cpx na CRF_11.cpx na 25.5 P 
01CM2274 CRF_02.AG na CRF_02.AG na 22.6 P 
01CM2275 CRF_09.cpx CRF_02.AG nd CRF_09.cpx 24.5 P 
01CM2276 CRF_11.cpx na CRF_11.cpx na 23.9 P 
01CM2277 CRF_11.cpx CRF_11.cpx nd CRF_11.cpx 21.4 P 
01CM2278 B na CRF_02.AG na 24.2 P 
01CM2280 CRF_11.cpx CRF_02.AG nd CRF_02.AG 29.8 P 
01CM2281 CRF_02.AG CRF_02.AG nd CRF_02.AG 23.4 P 
01CM2284 CRF_11.cpx CRF_11.cpx nd CRF_11.cpx 24.5 P 
01CM2287 CRF_11.cpx na CRF_01.AE na 33.2 P 
02CM319 ndb Od nd O No Tt Nh 
a Genotyping based on part of gag-p24 (460 bp), env-C2V3 (approximately 550 bp), pol-integrase, and env-gp41 
(approximately 405 bp) regions; b not detected;  c not available;  d Group O;  e threshold time by LA-200;  f 
agarose gel electrophoresis; g positive; and h negative. 
 
 






F3 5’-GGTAAGAGATCAGGCTGAACATC-3’ 4721-4743 
F2 5’-AGACAGCAGTACAAATGGCA-3’ 4747-4766 
Loop F 5’-TTAAAATTGTGGATGAAT-3’ 4786-4769 
F1c 5’-CCCCAATCCCCCCTTTTCTT-3’ 4806-4787 
B1c 5’-AGTGCAGGGGAAAGAATAGTAGAC-3’ 4812-4835 
Loop B 5’-GCAACAGACATACAAACTAAAG-3’ 4842-4863 
B2 5’-CTGCTGTCCCTGTAATAAACCC-3’ 4921-4900 
B3 5’-GCTGGTCCTTTCCAAAGTGG-3’ 4945-4926 
FIP  F1c + F2  
BIP  B1c + B2  
   * in HIV-1HXB2 
 
